- |||||||||| ALT 836 / NantWorks
Journal: Tissue factor-specific ultra-bright SERRS nanostars for Raman detection of pulmonary micrometastases. (Pubmed Central) - Oct 31, 2018
These mice were intravenously administered SERRS NPs conjugated with ALT-836, an anti-tissue factor (TF) monoclonal antibody, and subjected to Raman imaging to visualize the expression of TF both in vivo and ex vivo...Successful detection and delineation of pulmonary micrometastatic lesions as small as 200 μm, corroborated by histology, immunohistochemistry, and bioluminescence imaging confirmed the suitability of both TF as a target and αTF-SERRS-NPs as an effective contrast agent for imaging breast cancer lung metastases. Further advancements of this technique in the form of Raman endoscopes coupled with ultrabright SERRS NPs developed in this work could lead to minimally invasive detection and resection of lung metastases.
- |||||||||| ALT 836 / NantWorks
Journal: ImmunoPET imaging of tissue factor expression in pancreatic cancer with (89)Zr-Df-ALT-836. (Pubmed Central) - Jun 8, 2018
Taken together, these results attest to the excellent affinity and TF-specificity of (89)Zr-Df-ALT-836 in vivo. With elevated, persistent, and specific accumulation in TF-positive BXPC-3 tumors, PET imaging using (89)Zr-Df-ALT-836 promises to open new avenues for improving future diagnosis, stratification, and treatment response assessment in pancreatic cancer patients.
- |||||||||| carotuximab IV (TRC105) / Santen, Tracon Pharma, ALT 836 / ImmunityBio
Biomarker, Journal: ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment. (Pubmed Central) - Feb 22, 2018
PET imaging ofCu-NOTA-heterodimer-ZW800 in BxPC-3 tumor xenografts revealed enhanced tumor uptake (21.0 ± 3.4%ID/g; n = 4) compared to the homodimer of TRC-105 (9.6 ± 2.0%ID/g; n = 4; p < 0.01) and ALT-836 (7.6 ± 3.7%ID/g; n = 4; p < 0.01) at 24 h postinjection...Also, fluorescence imaging validated the PET imaging, allowing for clear delineation of the xenograft tumors. Dual-labeled heterodimeric imaging agents, like (64)Cu-NOTA-heterodimer-ZW800, may increase the overall tumor accumulation in comparison to single-targeted homodimers, leading to improved imaging of cancer and other related diseases.
- |||||||||| ALT 836 / ImmunityBio
Trial completion, Combination therapy, Metastases: A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jul 15, 2016
P1, N=30, Completed,
Dual-labeled heterodimeric imaging agents, like (64)Cu-NOTA-heterodimer-ZW800, may increase the overall tumor accumulation in comparison to single-targeted homodimers, leading to improved imaging of cancer and other related diseases. Active, not recruiting --> Completed
|
